Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide within the internal region of residues 200-300 of the human ATP13A2 protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||sodium borate|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||10-20 µg/ml|
|Western Blot (WB)||2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: human and mouse brain membrane prep lysate.
Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders. ATP13A2, otherwise known as PARK9, is a neuronal P-type ATPase gene underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia. ATP13A2 protein is located in the membrane of these lysosomes and is formed most strongly in the brain, especially in the substantia nigra, a brain region which is known to play a central role in Parkinson?s disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
ATPase type 13A2; HSA9947; KRPPD; PARK9; probable cation-transporting ATPase 13A2; putative ATPase; RP1-37C10.4
1110012E06Rik; AA589443; ATP13A2; CLN12; HSA9947; KRPPD; PARK9